D.A. Davidson & Co’s Tvardi Therapeutics TVRD Stock Holding History

D.A. Davidson & Co’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4	Closed	-$2K	–	2024
2017 Q2	$2K	Buy	4 +1	+33%	+$635	﹤0.01%	2302
2017 Q1	$2K	Buy	+3	New	+$1.6K	﹤0.01%	2276

Other funds holding TVRD

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.A. Davidson & Co's TVRD Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 4 shares — an estimated $2K sold.

D.A. Davidson & Co first reported a position in TVRD in Q1 2017 and held it in 2 quarters. The position peaked at $2K in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

D.A. Davidson & Co reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 4 Tvardi Therapeutics shares in Q3 2017, an estimated $2K.
D.A. Davidson & Co first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 2 quarters.
D.A. Davidson & Co's Tvardi Therapeutics position peaked at $2K in Q2 2017.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.